Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Clinical trial NCT06937086 · RECRUITING
Trial details
- NCT number
- NCT06937086
- Sponsor
- Eli Lilly and Company
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-26
- Primary completion
- 2028-04-01
- Enrollment
- 350
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.